18F-FDG PET/CT Evaluation of Ceritinib Therapy in Metastatic ALK-Positive Non–small Cell Lung Cancer

ABSTRACTAnaplastic lymphoma kinase (ALK)–positive non–small cell lung cancers (NSCLC) account for 3% to 7% of all NSCLC and require a standard treatment by crizotinib. However, crizotinib resistance is frequent within the first 12 months of treatment. Ceritinib is a novel tyrosine kinase inhibitor o...

Full description

Saved in:
Bibliographic Details
Published in:Clinical nuclear medicine 2016-11, Vol.41 (11), p.879-880
Main Authors: Dejust, Sebastien, Morland, David, Fabre, Guillaume, Prevost, Alain, Papathanassiou, Dimitri
Format: Article
Language:English
Subjects:
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - therapeutic use
Bioengineering
Carcinoma, Non-Small-Cell Lung - diagnostic imaging
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - genetics
Carcinoma, Non-Small-Cell Lung - pathology
Fluorodeoxyglucose F18
Humans
Life Sciences
Lung Neoplasms - diagnostic imaging
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
Lung Neoplasms - pathology
Neoplasm Metastasis
Nuclear medicine
Positron Emission Tomography Computed Tomography
Protein Kinase Inhibitors - administration & dosage
Protein Kinase Inhibitors - therapeutic use
Pyrimidines - administration & dosage
Pyrimidines - therapeutic use
Radiopharmaceuticals
Receptor Protein-Tyrosine Kinases - genetics
Sulfones - administration & dosage
Sulfones - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACTAnaplastic lymphoma kinase (ALK)–positive non–small cell lung cancers (NSCLC) account for 3% to 7% of all NSCLC and require a standard treatment by crizotinib. However, crizotinib resistance is frequent within the first 12 months of treatment. Ceritinib is a novel tyrosine kinase inhibitor of ALK recently introduced in France for metastatic or locally advanced crizotinib-resistant ALK NSCLC. We report the first use of ceritinib in our institution with a spectacular tumoral response after only 3 months of treatment. This case demonstrates the major role of F-FDG PET/CT for monitoring the effectiveness of this new treatment.
ISSN:0363-9762
1536-0229
DOI:10.1097/RLU.0000000000001361